Burjeel and Avatrial Collaborate for AI-Driven Cancer Drug Discovery
Abu Dhabi-based Burjeel Holdings has signed a memorandum of understanding with British biotechnology company Avatrial during the Abu Dhabi Future Health Summit to explore the development of an AI-powered cancer drug discovery ecosystem. The proposed collaboration combines clinical data, multi-layered molecular analysis, and patient-derived laboratory models.